The platelet membrane glycoprotein (GP) Ib complex consists of four polypeptides: the disulfide-linked Gplba and Gplbp subunits; GplX, tightly, but noncovalently associated with Gplba-p; and the more weakly associated GpV. It is not certain whether the association of GpIX t o Gplba-fi is via Gplba, Gplbp, or both subunits, although recently published evidence implicates an interaction with Gplbp. We have investigated the interaction of GplX with Gplba-p using polyclonal rabbit antibodies t o Gplba and Gplbp raised by immunization with purified glycocalicin and with synthetic peptide sequences from Gplbp, respectively, as well as monoclonal antibodies directed against GplX (FMC-25) and against Gplba (AP-1). We performed t w o types of experiments, using either purified Gplb complex or platelets.
When wells were coated with polyclonal Gplba or Gplbp antibodies and then incubated with reduced Gplb complex, only wells coated with Gplba antibodies captured GplX reactivity. When wells were coated with FMC-25 and then incubated with nonreduced Gplb complex, both the Gplba and Gplbp polyclonal antibodies reacted strongly; in contrast, only Gplba reactivity was retained when wells coated with FMC-25 were incubated with reduced Gplb complex. In the reciprocal experiment, AP-1 -coated wells incubated with either nonreduced or reduced Gplb complex bound radiolabeled FMC-25. ( 2) The ability of polyclonal Gplba and Gplbp antibodies t o inhibit binding of FMC-25 t o platelets was studied by ELSA and by flow cytometry. In both systems, FMC-25 binding was inhibited by the Gplba antibody, but not significantly by the Gplbp antibody. We conclude that GplX is strongly associated with Gplba in the purified platelet Gplb complex and in the platelet membrane. 0 1996 by The American Society of Hematology.
MATERIALS AND METHODS

Mutprials
Monoclonal antibodies (MoAbs) to GplX (FMC-25) and Gplba (AP-l) were generously supplied by Dr Michael Bemdt (University of Sydney, Australia), and Dr Robert Montgomery (The Blood Center of Southeastern Wisconsin, Milwaukee, WI), respectively."" Sheep antiglycocalicin antiserum was a gift of Drs N. Tandon and G. Jamieson (The American Red Cross Jerome H. Holland Laboratory, Rockville, MD). Secondary antibodies were obtained from Kirkegaard and Perry Laboratories, Inc (Gaithersburg, MD) and Pierce (Rockford, IL). RIB1 adjuvant was purchased from RIB1 ImmunoChem Research, Inc (Hamilton, MT). Sepharose 4B, PD-IO columns, wheat germ agglutinin (WGA) Sepharose 6MB, Protein G Superose and Mono-Q Superose were obtained from Pharmacia Biotech (Piscataway, NJ). Succinimidyl-4-(N-maleimidomethyI) cyclohexane-1 -carboxylate (SMCC) was obtained from Pierce. Keyhole limpet hemocyanin was purchased from Calbiochem (La Jolla, CA). Affigel-l0 was purchased from Bio-Rad Laboratories (Hercules, CA). All other reagents were purchased from Sigma Chemical CO (St Louis, MO). MoAb FMC-25 was radiolabeled with NaIZ5I (ICN Biochemicals. Costa Mesa, CA) using the method of Fraker and Speck."
Preparation of glycocalicin und Gplb complex. Glycocalicin (GC), the extracellular portion of GpIba, was prepared essentially as described.I3.l4 Fifty-unit batches of 6 to 7 day outdated platelet concentrates (obtained from the American Red Cross, Penn-Jersey Region, Philadelphia, PA) were washed three times in 20 m m o E Tris-HCI, 0.15 mol/L NaCI, and I O mmol/L Na2EDTA, pH 7.5 (STE), and resuspended in 3 moliL KC1 for 30 minutes at room temperature. The suspension was centrifuged at 3,000 rpm for 15 minutes at room temperature and the supernatant fraction was passed over a IO mL WGA Sepharose column and eluted with 100 mmol/ L N-acetyl-D-glucosamine. Fractions containing Gc were pooled and concentrated by absorption on a Mono-Q 5/5 column and elution with a 0.1 to 0.7 molL NaCl gradient. GC was separated from lower molecular weight contaminants by gel filtration on a 1.5 X 100 cm Sepharose CL-6B column and concentrated by ultrafiltration. In reduced and nonreduced sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) the purified GC consisted of one band at approximately 120 kD. GpIb-1X complex was purified from washed platelets which were lysed by the addition of an equal volume of 1% Triton X-l00 in STE containing 5 U/mL DNase I and protease inhibitors (0.1 mg/mL leupeptin, 400 KIUlmL aprotinin, 1 mmol/L phenylmethylsulfonyl fluoride, 15 pg/mL pepstatin A). The lysate was applied to the WGA-Sepharose column, washed, eluted with N-acetyl-D-glucosamine (100 mmoVL) in STE with 0.1% Triton X-100, dialyzed against STE and applied to an anti-GpIba (AP-1) MoAb Sepharose column." After washing with 0.5 m o m NaCl in the same buffer, the column was eluted with 0.05 m o m diethanolamine, pH 11.5. Fractions were neutralized with 1 m o m Tris-HC1. The GpIb complex so prepared contains GpIX but does not contain immunologically detectable amounts of GpV.
Preparation of polyclonal antibodies against GpIba and Gplbp. To prepare antibodies against GpIba, rabbits were immunized with purified human GC by subcutaneous injection, using RIB1 adjuvant. To prepare GpIbp antibodies, two peptides from the platelet GpIbp chain (residues 81-93 and 101-108) were synthesized and coupled to keyhole limpet hemocyanin, using SMCC as de~cribed,'~ and mixed with RIB1 adjuvant. Rabbits were immunized monthly by subcutaneous injection. Immune sera were obtained after four or five immunizations. Antibodies were detected by immunodiffusion against purified GC or GpIb complex and antibody titers were determined by enzyme linked immunosorbent assay (ELISA) in wells coated with either GC or the GpIbP peptides coupled to bovine serum albumin (BSA). IgG was isolated from immune serum using protein G-Superose. The anti-GpIbp IgG was further purified by one of two methods: (1) Total IgG was passed through a keyhole limpet hemocyanin-Affigel-l0 column followed by affinity purification on a column of BSA-coupled GpIbp peptides linked to Sepharose-4B; (2) GpIbP peptides were reduced using an immobilized reducing agent (Reduce-Imm, Pierce) and attached to a 2 mL SulfoLink (Pierce) matrix. Total IgG first was passed over a similar column with an irrelevant peptide attached, and the effluent was loaded onto the specific peptide column, which was extensively washed with phosphate buffered saline (PBS). Specifically bound immunoglobulins were eluted with 0.1 m o m glycine pH 2.7. Fractions were neutralized using 1 m o m Tris-base. The purified polyclonal antibodies were characterized by Western blotting of reduced (5% p-mercaptoethanol) and nonreduced SDS-polyacrylamide gels. For use as a positive control, polyclonal mouse antihuman platelet antibodies were prepared in our laboratory.
Methods
Direct EWSA. An ELISA assay was used to determine the immunoreactivity of reduced and nonreduced GpIb-IX complex against purified polyclonal GpIba and GpIbP antibodies. Reduced complex was prepared by incubation of GpIb complex with 5% P-mercaptoethanol for 30 minutes. Wells were coated with either reduced or nonreduced GpIb complex (100 pL of a 5 pg/mL solution in 100 mmol/L. NaHC03/Na2C03, pH 9.6) overnight at 4"C, washed three times with 200 pL PBS (20 mmol/L phosphate, 150 mmom NaCl, pH 7.4) containing 0.05% Tween-20 (PBS-T), blocked with 200 pL 3% BSA in PBS-T for 2 hours, washed three. times with PBS-T, and incubated for 1 hour with 100 pL polyclonal anti-GpIba (1 pg/ mL) or anti-GpIbp (4 pg/mL). The wells were washed three times with PBS-T, incubated for 1 hour with 100 pL peroxidase-labeled goat antirabbit IgG, washed six times with PBS-T, after which the substrate, TMB (3,3',5,5' tetramethylbenzidine), was added. Absorbance at 650 nm was measured after 10 minutes in a multichannel photometer (Dynatech Instruments, Chantilly, MD). As an antigen control, wells were coated with 5 pg/mL BSA instead of with GpIb complex. As an antibody control, purified pre-immune rabbit IgG (1 pg/mL) was substituted for the polyclonal antibodies.
Competitive EWSA. Microtiter wells were coated and blocked as above. Reduced and nonreduced GpIb complex-coated wells were divided into four groups. In the first group, 100 pL of 2 pg/mL FMC-25 was added to each well. In the second group, 50 pL of 4 pg/mL FMC-25 and 50 pL of 40 pg/mL purified polyclonal antiGpIba were added to each well. In the third group 50 pL of 4 pg/ mL FMC-25 and 50 pL of 40, 80, or 160 pg/mL purified polyclonal anti-GpIbp were added. In the fourth group (the control group), 50 pL of 4 pg/mL FMC-25 and 50 pL of 40 pg/mL purified preimmune rabbit IgG were added to each well. All wells were allowed to incubate for 1 hour, washed four times with PBS-T, incubated for 1 hour with 100 pL of peroxidase-labeled goat antimouse IgG and then washed six times with PBS-T. The substrate, TMB, was then added and absorbance was measured as above. In some experiments washed platelets (2 X lo6 in 100 pL) were either gluteraldehyde-fixed and coated on microtiter wells or coated on microtiter wells and then fixed, and finally blocked with 3% BSA. Coated wells were divided into four groups: one group was incubated with 2 pg/mL FMC-25 alone, the second group was incubated with FMC-25 and 60 p@mL normal rabbit IgG. The third group was incubated with FMC-25 and 20, 40, 60, or 120 pg/mL anti-GpIba IgG. The last group was incubated with FMC-25 and 20,40, 60, 120, or 240 pg/mL affinity purified anti-GpIbp IgG. All wells were allowed to incubate for 1 hour and processed as above.
Antigen capture ELISA. (1) Groups of microtiter wells were coated with either 100 pL of 5 pg/mL purified polyclonal antiGpIba, IO pg/mL anti-GpIbp, or 5 pg/mL pre-immune IgG. Each set of wells was then incubated with either reduced or nonreduced GpIb complex and washed four times with PBS-T. Each set of wells was divided into 4 subgroups and incubated with either anti-GpIba
MoAb A P -1 , anti-GpIX MoAb FMC-25, mouse antihuman platelet antiserum, or normal mouse IgG. The wells were washed four times, incubated for 1 hour with 100 pL of peroxidase-labeled goat antimouse IgG, and then washed and developed as above. (2) Another group of microtiter wells was coated with 5 pg/mL FMC-25 (100 pL/well), washed three times with PBS-T, and blocked with 3% BSA. The wells were then incubated for 1 hour with 100 pL of nonreduced or reduced GpIb complex (4 pg/mL in BSA-PBS-T), washed four times, and incubated for 1 hour with either 100 pL of 1 pg/mL polyclonal anti-GpIba, 2 or 4 pg/mL polyclonal antiGpIbp, or pre-immune rabbit IgG. The wells were then washed four times, incubated for 1 hour with 100 pL of peroxidase-labeled goat antirabbit IgG, and washed and developed as above. In another series of experiments microtiter wells were coated with 100 pL of 5 pg/ mL AP-l, washed, and blocked with 3% BSA. The wells were incubated for 1 hour with 100 pL of reduced or nonreduced GpIb complex, washed four times and incubated for 1 hour with 1251-labeled FMC-25 followed by six washes. Bound cpm were detected using a Beckman 5500 gamma counter. Flow cytometry. Gel-filtered platelets" were incubated for 1 hour with 2 pglmL FMC-25 alone, 2 pglmL FMC-25 plus 60 pg/ mL normal rabbit IgG, or 2 pg/mL FMC-25 plus varying concentrations of either rabbit anti-GpIba IgG (20, 40, 60, or 120 pg/mL) or rabbit anti-GpIbp IgG (20,40,60, 120, or 240 pg/mL). The platelets were washed three times with PBS, incubated with a 1:lO dilution of FITC-conjugated goat antimouse IgG (Fah')?, washed three times with PBS, and analyzed using a Coulter EPICS Profile I1 fluorescence-activated cell sorter (Coulter Corp, Hialeah, FL). Data are reported as changes in mean log fluorescence intensity. Fig 1, 4) conditions, transferred t o nitrocellulose, blotted, and incubated with either 1 pg/mL purified rabbit polyclonal anti-Gplba IgG (lanes 1 and 2) . 4 pg/mL affinity purified rabbit polyclonal anti-Gplbp IgG (lanes 3 and 4) , or 2 pglmL FMC-25 (lane 51 and detected with alkaline phosphatase-labeled goat antirabbit IgG or goat antimouse IgG.
RESULTS
As shown in
nonreduced or reduced Gplb complex, respectively. MoAb FMC-25 detected a single band at 22 kD on nonreduced gels, but reacted poorly on reduced gels. As shown in Table  I . both polyclonal antibodies and FMC-25 reacted strongly against reduced and nonreduced GpIb complex coated on microtiter wells, compared with BSA or pre-immune IgG controls, although absorbance values obtained with reduced complex were slightly lower than those seen with nonreduced complex.
To examine the effect of polyclonal GpIba or Gplbp antibodies on the binding of MoAb FMC-25 to the Gplb complex, a competitive ELISA was used. As shown in Fig 2, FMC-25 binding to nonreduced Gplb complex was inhibited 73% by the Gplba antibody and only 30% by the GpIbP antibody, suggesting that GpIX may be more closely associated with Gplba than with GpIbp. When the Gplb complex was reduced (under conditions that on Western blotting indicated total dissociation of Gplba and Gplbp) and coated on microtiter wells, anti-Gplba IgG inhibited FMC-25 binding by 86%. while anti-GpIbp IgG inhibited FMC-25 binding by only 13%. compared with 5% inhibition by normal rabbit IgG.
To investigate further the relationship between GpIba, GpIbp, and GplX, we examined the nature of the antigen(s) captured on microtiter wells coated with antibodies to Gplba, Gplbp, or GplX. As shown in Fig 3A, the GpIX MoAb FMC-25 reacted strongly with the antigen(s) captured by polyclonal GpIba antibody when either reduced or nonreduced Gplb complex was added, although immunoreactivity was slightly lower when reduced complex was used. As expected, the Gplba MoAb AP-I and the mouse antihuman platelet antiserum both reacted strongly in this system. Low absorbance values were found when normal mouse IgG (negative control) was substituted for specific antibodies. As shown in Fig 3B, both AP-I and FMC-25 reacted with the antigen(s) captured by polyclonal GpIbg antibody when nonreduced Gplb complex had been added. In contrast, neither AP-1 nor FMC-25 reacted with wells coated with polyclonal Gplbp antibody when reduced Gplb complex was incubated in the well. As expected, mouse antihuman platelet antiserum reacted strongly with reduced and unreduced Gplb complex, while low absorbance values were found when normal mouse IgG was added. In an effort to obtain more direct data concerning the GpIba-GplX interaction, the GpIba MoAb AP-I was used to capture either nonreduced or reduced Gplb complex and radiolabeled FMC-25 was added. These experiments indicate that in the purified GpIb complex GpIX is associated with the GpIba chain, rather than the GpIbP subunit. We sought to determine if this relationship held true on the platelet surface. In a series of experiments, platelets coated on microtiter wells were incubated either with FMC-25 alone or with a mixture of FMC-25 and increasing concentrations of GpIba or GpIbP polyclonal antibody. As shown in Fig 5, GpIba IgG inhibited FMC-25 binding to the platelet surface in a concentration-dependent manner. In contrast, anti-GpIbP IgG had little effect on FMC-25 binding. Since these experiments use fixed platelets, we performed an additional series of experiments using fresh platelets. Gel-filtered platelets were incubated with FMC-25 (2 pg/mL) alone or with mixtures of FMC-25 and either GpIba or GpIbP antibodies and bound FMC-25 was detected by flow cytometry. When platelets were incubated with 20, 40, 60, or 120 pg/mL GpIba antibody, FMC-25 binding was reduced by 30%, 38%, 4570, and 56%, respectively. In contrast, 20, 40, 60, 120, or 240 pg/mL GpIbP antibody inhibited FMC-25 binding by 0%, 6%. 12%, 14%. and 22%. respectively. These results are identical to those obtained in the ELISA system using fixed platelets. In these experiments similar and substantial amounts of radioactivity bound to the wells when either reduced or nonreduced complex was added (Table 2) , again indicating an interaction between the captured GpIba and the added GpIX, even after reduction. In the converse experiment, as shown in Fig 4, the antigen(s) captured on microtiter wells coated with FMC-25 and incubated with nonreduced GpIb complex reacted with both GpIba and GpIbP antibodies. In contrast, only Gplba antibodies reacted with FMC-25-coated wells incubated with reduced GpIb complex. When BSA was added to microtiter wells in place of GpIb complex no increase in cpm was found. In additional experiments, FMC-25-coated microtiter wells were incubated with nonreduced GpIb complex and we examined the ability of a series of 6 GpIba MoAbs (80 pg/mL) to inhibit binding of the polyclonal GpIbP IgG (4 pg/mL). The GpIba MoAbs inhibited anti-GpIbp IgG binding by 37% to 67% (data not shown). 
DISCUSSION
The GpIb complex consists of four polypeptide chains only two of which, GpIba and GpIbP, are covalently linked. GpIX interacts strongly, but noncovalently, with GpIba-P, but the nature of this interaction has not been established. Recently, Lopez et a1," in elegant experiments with transfected cells, reported that GpIbP was crucial for the synthesis and the surface expression of both GpIX and GpIba. In that report, no evidence of a GpIba-GpIX association was found. In this report, we have used both purified GpIb complex and whole platelets to study the interaction of GpIX with GpIba-P. In both systems we obtained evidence for an association between GpIX and GpIba, and no evidence of an association between GpIX and GpIbP. The apparent contradiction between our results and those of Lopez et a1 might have a number of explanations. Several potential problems might arise in studying interactions using the purified GpIb complex. For example, it is conceivable that the steps used to isolate the GpIb complex may have altered, in some manner, one of the subunits of the complex and, therefore, the interactions of the component polypeptides. Although we cannot completely rule out such a possibility, direct examination of whole platelet lysates, prepared either with Triton X-l00 or digitonin, gave results identical with those we have observed with the isolated complex (data not shown). A second possibility might be that removal of the detergent, which occurs as part of the purification of the complex, might have contributed to artifactual results in the ELISA assays. However, we have examined the platelet lysates in the presence of 1% digitonin-a condition in which the reactivities of the antibodies we used are unaffectedand obtained results identical with those seen with purified complex. A third possible problem is that all three of the antibodies we used, particularly the polyclonal anti-GpIbP, reacted somewhat less well against reduced than against nonreduced complex. Nevertheless, it seems unlikely that this small loss in sensitivity could account for a total loss of our ability to detect complex formation between GpIbP and GpIX. Finally, the nature of ELISA assays, which involve multiple wash steps, might result in failure to detect weak interactions between GpIbP and GpIX. None of these considerations would explain our finding of a strong interaction between GpIX and GpIba.
Nevertheless, studies of isolated membrane complexes cannot be as informative as studies of the complex in situ.
We therefore measured the ability of our antibodies to compete for antigen on the platelet surface, using ELISA (with fixed platelets) and flow cytometry (using unfixed platelets). The polyclonal antibodies to GpIba and GpIbp, as well as the monoclonal antibodies to GpIba and GpIX, each bind well to the platelet surface. In the whole platelet systems our results lead to the same conclusions we reached using purified GpIb complex: GpIX appears to interact with GpIba, not GpIbp.
Lopez et a1 previously demonstrated that C H 0 cells express GpIba efficiently on the plasma membranei7 only if triply transfected with cDNAs for GpIba and GpIbP and GpIX. Their more recent experiments, using C H 0 and L cells transfected with only two of the three cDNAs, suggest that GpIbP is essential for efficient expression of GpIba and of GpIX.'" The direct evidence for a GpIbP-GpIX association was from a series of immunoprecipitation experiments. In cells cotransfected with GpIbP and GpIX, antibodies to either component precipitated both. On the other hand, in cells cotransfected with GpIba and CpIX, neither a GpIba MoAb nor a GpIX MoAb coprecipitated the other molecule of the complex. However, in those experiments FMC-25 (the GpIX MoAb) also failed to precipitate GpIX, suggesting that cells cotransfected with GpIba and GpIX express very little GpIX. The inefficient expression of GplX in these cells may account for the inability to detect an interaction between GpIba and GpIX, perhaps even when these cells were transiently transfected with GpIbp. Finally, as clearly stated in the report by Lopez et al, the results they obtained were largely representative of the intracellular, rather than membrane, pool of the three polypeptide chains and. therefore, might be a function of intracellular conditions, such as the heterogeneity in glycosylation which they observed. Nevertheless, the work of Lopez et al makes clear that the GpIbP subunit plays a very significant role in directing the translation and processing of the GpIb complex.
The present study examines the interactions between the components of the GpIb membrane complex isolated from normal human platelets, and between the same components within the platelet membrane. Our results indicate a close association between GpIX and GpIba, rather than GpIbp. and are consistent with a previous report' of a 35% inhibition of FMC-25 binding to platelets by affinity-purified rabbit anti-GpIba IgG. Taken together, our results and those of Lopez et al suggest that GpIX may interact with both GpIba and GpIbP, possibly at different times during the expression of the complex. Further studies are needed in order to define more precisely the interactions of these polypeptides.
